ReviewExpert review of cardiovascular therapy2005
ROCKs as therapeutic targets in cardiovascular diseases.
Review in Expert review of cardiovascular therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 72 citations in OpenAlex.
- Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation.Circulation · 2009 · on this mapTrial
- [Expression of Rho-related BTB domain-containing protein 1 in tongue squamous cell carcinoma and its effect on cell proliferation, invasion, and migration].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2026Article
- Crosstalk Between Signaling Stroke Cascade and Therapeutic Receptors PPAR-γ, ROCK, CB1R, and CB2R: From Mechanism to Therapies.Translational stroke research · 2025Review
- Selective ROCK Inhibitor Enhances Blood Flow Recovery after Hindlimb Ischemia.International journal of molecular sciences · 2023Article
- Kinome-Wide Profiling Identifies Human WNK3 as a Target of Cajanin Stilbene Acid fromInternational journal of molecular sciences · 2022Article
- Review
- Reactive oxygen species in cardiovascular health and disease: special references to nitric oxide, hydrogen peroxide, and Rho-kinase.Journal of clinical biochemistry and nutrition · 2020Review
- Article
- Article
- Evaluation of Rho-kinase activity in mice brain using N-[11C]methyl-hydroxyfasudil with positron emission tomography.Molecular imaging and biology · 2014Article
- Ser1333 phosphorylation indicates ROCKI activation.Journal of biomedical science · 2013Article
- Rho-kinase inhibitor Y-27632 attenuates pulmonary hypertension in hyperoxia-exposed newborn rats.Acta pharmacologica Sinica · 2013Article
- Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.Journal of cardiovascular pharmacology · 2013Review
- Role of Rho kinase isoforms in murine allergic airway responses.The European respiratory journal · 2011Article
- A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells.Science signaling · 2011Article
- Rho kinase as a therapeutic target in cardiovascular disease.Future cardiology · 2011Review
- Blood vessel tubulogenesis requires Rasip1 regulation of GTPase signaling.Developmental cell · 2011Article
- Recent achievements in the management of Raynaud's phenomenon.Vascular health and risk management · 2010Review
- Rho kinase-1 mediates cardiac fibrosis by regulating fibroblast precursor cell differentiation.Cardiovascular research · 2009Article
- Analysis of pulmonary vasodilator responses to SB-772077-B [4-(7-((3-amino-1-pyrrolidinyl)carbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin-2-yl)-1,2,5-oxadiazol-3-amine], a novel aminofurazan-based Rho kinase inhibitor.The Journal of pharmacology and experimental therapeutics · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
There is growing evidence that Rho-kinases (ROCKs), the immediate downstream targets of the small guanosine triphosphate-binding protein Rho, may contribute to cardiovascular disease. ROCKs play a central role in diverse cellular functions such as smooth muscle contraction, stress fiber formation and cell migration and proliferation. Overactivity of ROCKs is observed in cerebral ischemia, coronary vasospasm, hypertension, vascular inflammation, arteriosclerosis and atherosclerosis. ROCKs, therefore, may be an important and still relatively unexplored therapeutic target in cardiovascular disease. Recent experimental and clinical studies using ROCK inhibitors such as Y-27632 and fasudil have revealed a critical role of ROCKs in embryonic development, inflammation and oncogenesis. This review will focus on the potential role of ROCKs in cellular functions and discuss the prospects of ROCK inhibitors as emerging therapy for cardiovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.